Waters expands mass spectrometry portfolio to fast-track drug development

Waters Corporation has recently introduced new software, instruments and product enhancements to accelerate the drug discovery and development at the ASMS (American Society for Mass Spectrometry) 2022 Annual Conference.

The products under these innovations include the CONFIRM Sequence – an advanced oligonucleotide sequencing authorization app for the waters_connect™ software platform, a new Xevo™ G3 QTof (quadrupole time-of-flight) mass spectrometer, and an electrospray ionization basis for the multi spectral Waters™ SELECT SERIES™ (MRT Multi-Reflecting Time) of Flight mass spectrometer.

Jon Pratt, Senior Vice President at Waters Corporation, said that the innovations in mass spectrometry advance swiftly.

Jon added that the new product portfolio is anticipated to benefit scientists throughout the drug development cycle.

For researchers, this would mean boosting the capability for resolving fundamental scientific questions while for the analytical scientist accumulating analytical data to file a new drug, it means enlarged certainty and self-assurance in knowing exactly what is in the testers and in what quantities.

The novel Xevo G3 QTof system, amongst the many unveiled, is a sophisticated, benchtop mass spectrometer for quantifying and characterizing molecules in applications like forensics, biotherapeutics, metabolomics, metabolite identification, and leachables and extractables.

The product is 10 times more sensitive than its predecessor at transferring thermally fragile molecules and excels at characterizing and measuring native or denatured peptides, proteins, and other biotherapeutics.

Dr. Andrew Mahan, Mass Spectrometry Group Leader, Associate Director of Cell Engineering & Early Development, Janssen, said that the biopharmaceutical commercialization and development requires a deep understanding of product distinction, the degradation pathways, and procedures that make them.

It has been claimed that the protracted mass-to-charge ratio (m/z) series of the Xevo G3 QTof is expected to be idyllic for analyzing multi-specifics and instinctive MS analyses.

Waters developed the Xevo G3 QTof system to consistently offer scientists the reproducible and exact qualitative and quantitative information related to molecules in their samples, whether in very large or very small amounts.

Source Credit - https://www.socialnews.xyz/2022/06/06/waters-introduces-high-resolution-mass-spectrometry-products-and-software-to-accelerate-drug-development/